{'Misc.': ['', '\xc3\x82\xe2\x80\xa0\xe2\x80\x9c = DECREASED (INDUCES LAMOTRIGINE GLURONIDATION). \xc3\x82\xe2\x80\xa0\xe2\x80\x98 = INCREASED (INHIBITS LAMOTRIGINE GLUCURONIDATION). ? = CONFLICTING DATA.', 'BLOOD\xc3\x82\xc2\xa0DYSCRASIAS\xc3\x82\xc2\xa0\xc3\x82\xe2\x82\xac\xe2\x80\x9d', '*RANGE', 'HYPOTHYROIDISM', 'DOSING\xc3\x82\xc2\xa0SCHEDULE', 'DIARRHEA', 'TISSUE', 'DIARRHEA ELEVATED TEMPERATURE HEPATIC DISORDERS INFECTIOUS HEPATITIS JAUNDICE', 'EDEMA', 'HYPOTHYROIDISM NEPHROTIC SYNDROME', 'HYPERTHYROIDISM', 'RAT HEPATOCYTE DNA REPAIR ASSAY', 'HYPERTHYROIDISM POOR NUTRITIONAL STATE STEATORRHEA VITAMIN K DEFICIENCY', 'N A', 'DOSE SCHEDULE', 'EDEMA HEREDITARY COUMARIN RESISTANCE HYPERLIPEMIA', 'LABORATORY TESTS', 'STORAGE', 'BLOOD DYSCRASIAS - SEE CONTRAINDICATIONS CANCER COLLAGEN VASCULAR DISEASE CONGESTIVE HEART FAILURE', 'INCREASED'], 'Sample Size': ['N'], 'Recommendation or Comment': ['RECOMMENDATIONS FOR DRUG DOSAGE ADJUSTMENT/COMMENTS', '*\xc3\x82\xc2\xa0 REFER TO PRECAUTIONS, DRUG INTERACTIONS FOR INFORMATION REGARDING TABLE.', 'TABLE IV. DRUGS THAT HAVE BEEN DOCUMENTED NOT TO INTERACT WITH THEOPHYLLINE OR DRUGS THAT PRODUCE NO CLINICALLY SIGNIFICANT INTERACTION WITH THEOPHYLLINE. REFER TO PRECAUTIONS, DRUG INTERACTIONS FOR INFORMATION REGARDING TABLE.', '\xc3\x82\xe2\x80\xa0\xe2\x80\x98 INDICATES INCREASE. \xc3\x82\xe2\x80\xa0\xe2\x80\x9c INDICATES DECREASE.', 'PRESCRIBING RECOMMENDATIONS', 'RECOMMENDATION', 'A = PLASMA CONCENTRATION INCREASED 25% IN SOME PATIENTS, GENERALLY THOSE ON A TWICE A DAY DOSING REGIMEN OF PHENYTOIN.', 'STRONG CYP3A4 (EG, KETOCONAZOLE) OR CYP2D6 (EG, FLUOXETINE) INHIBITORS WILL INCREASE ABILIFY DRUG CONCENTRATIONS; REDUCE ABILIFY DOSE BY ONE-HALF WHEN USED CONCOMITANTLY (2.6 , 7.1) , EXCEPT WHEN USED AS ADJUNCTIVE TREATMENT WITH ANTIDEPRESSANTS (2.6) CYP3A4 INDUCERS (EG, CARBAMAZEPINE) WILL DECREASE ABILIFY DRUG CONCENTRATIONS; DOUBLE ABILIFY DOSE WHEN USED CONCOMITANTLY (2.6 , 7.1)', 'NA \xc3\x82\xe2\x82\xac\xe2\x80\x9c NOT AVAILABLE/REPORTED', 'AVERAGE DURATION OF EFFECT', 'PRESCRIBING RECOMMENDATIONS FOR LIPTRUZET', 'NOTED OR ANTICIPATED OUTCOME', 'SYSTEMIC EXPOSURE TO KETOCONAZOLE IS REDUCED SIGNIFICANTLY BY THESE DRUGS: CONCOMITANT USE WITH KETOCONAZOLE IS NOT RECOMMENDED.', 'TABLE 4 DRUGS TESTED IN IN VITRO BINDING OR IN VIVO DRUG INTERACTION TESTING OR WITH POST-MARKETING REPORTS', 'MAY REQUIRE A DECREASE IN DOSE AT CESSATION OF SMOKING', 'SALMONELLA/MICROSOME TEST (NEGATIVE)', 'CAUTION\xc3\x82\xc2\xa0SHOULD\xc3\x82\xc2\xa0BE\xc3\x82\xc2\xa0EXERCISED\xc3\x82\xc2\xa0WHEN\xc3\x82\xc2\xa0COMBINING\xc3\x82\xc2\xa0DIGOXIN\xc3\x82\xc2\xa0WITH\xc3\x82\xc2\xa0ANY DRUG THAT MAY CAUSE SIGNIFICANT DETERIORATION IN RENAL FUNCTION (E.G., ACE INHIBITORS, ANGIOTENSIN RECEPTOR BLOCKERS, NONSTEROIDAL ANTI-INFLAMMATORY DRUGS [NSAIDS], COX-2 INHIBITORS) SINCE A DECLINE IN GLOMERULAR FILTRATION OR TUBULAR SECRETION MAY IMPAIR THE EXCRETION OF DIGOXIN.', 'DAY 1', 'DAY 5', 'RISPERIDONE DOSERECOMMENDATION', 'FREQUENT MONITORING FOR ADVERSE EVENTS AND TOXICITY RELATED TO NSAIDS. DOSE REDUCTION OF NSAIDS MAY BE NEEDED. [ SEE DRUG INTERACTIONS ( 7 ) ].', 'TABLE 5 EFFECTS ON STEADY-STATE FEXOFENADINE PHARMACOKINETICS AFTER 7 DAYS OF CO-ADMINISTRATION WITH FEXOFENADINE HYDROCHLORIDE 120 MG EVERY 12 HOURS IN HEALTHY ADULT SUBJECTS (N=24)', 'CONCOMITANT ADMINISTRATION WITH DIGOXIN WAS ASSOCIATED WITH A HIGHER RATE OF TORSADES DE POINTES.', 'TABLE 4. ESTABLISHED AND OTHER POTENTIALLY SIGNIFICANT DRUG INTERACTIONS', 'A = PLASMA CONCENTRATION INCREASED 25% IN SOME PATIENTS, GENERALLY THOSE ON A TWICE A DAY DOSING REGIMEN OF PHENYTOIN. B =\xc3\x82\xc2\xa0IS NOT ADMINISTERED BUT IS AN ACTIVE METABOLITE OF CARBAMAZEPINE. NC = LESS THAN 10% CHANGE IN PLASMA CONCENTRATION. NE = NOT EVALUATED.', '* THE INTERACTION BETWEEN VIRAMUNE AND THE DRUG WAS EVALUATED IN A CLINICAL STUDY. ALL OTHER DRUG INTERACTIONS SHOWN ARE PREDICTED.', 'IN VITRO STUDIES DEMONSTRATED POTENTIAL FOR VORICONAZOLE TO INHIBIT METABOLISM (INCREASED PLASMA EXPOSURE)', '\xc3\x82\xe2\x80\xa0\xe2\x80\x98INDICATES INCREASE. \xc3\x82\xe2\x80\xa0\xe2\x80\x9cINDICATES DECREASE.', 'AVOID ATORVASTATIN', '*RESULTS BASED ON IN VIVO CLINICAL STUDIES GENERALLY FOLLOWING REPEAT ORAL DOSING WITH 200 MG Q12H VORICONAZOLE TO HEALTHY SUBJECTS **RESULTS BASED ON IN VIVO CLINICAL STUDY FOLLOWING REPEAT ORAL DOSING WITH 400 MG Q12H FOR 1 DAY, THEN 200 MG Q12H FOR AT LEAST 2 DAYS VORICONAZOLE TO HEALTHY SUBJECTS *** NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS', 'TABLE 2: DRUG \xc3\x82\xe2\x82\xac\xe2\x80\x9d THYROIDAL AXIS INTERACTIONS', 'I. DUE TO THE COMPETITION OF SALICYLATE WITH OTHER DRUGS FOR BINDING TO SERUM ALBUMIN THE FOLLOWING DRUG INTERACTIONS MAY OCCUR:', '\xc3\x82\xe2\x80\xa0\xe2\x80\x9c = DECREASED (INDUCES LAMOTRIGINE GLUCURONIDATION).', 'A = PLASMA CONCENTRATION INCREASED 25% IN SOME PATIENTS, GENERALLY THOSE ON A B.I.D. DOSING REGIMEN OF PHENYTOIN. B = IS NOT ADMINISTERED BUT IS AN ACTIVE METABOLITE OF CARBAMAZEPINE. NC = LESS THAN 10% CHANGE IN PLASMA CONCENTRATION. AED = ANTIEPILEPTIC DRUG. NE = NOT EVALUATED. TPM = TOPIRAMATE', '\xc3\x82\xe2\x80\xa0\xe2\x80\x9c= DECREASED (INDUCES LAMOTRIGINE GLUCURONIDATION). \xc3\x82\xe2\x80\xa0\xe2\x80\x98= INCREASED (INHIBITS LAMOTRIGINE GLUCURONIDATION). ?= CONFLICTING DATA.', 'RECOMMENDATIONS', '\xc3\x82\xe2\x80\xa0\xe2\x80\x9c= DECREASED (INDUCES LAMOTRIGINE GLURONIDATION). \xc3\x82\xe2\x80\xa0\xe2\x80\x98= INCREASED (INHIBITS LAMOTRIGINE GLURONIDATION). ?= CONFLICTING DATA.', '*RESULTS BASED ON IN VIVO CLINICAL STUDIES GENERALLY FOLLOWING REPEAT ORAL DOSING WITH 200 MG BID VORICONAZOLE TO HEALTHY SUBJECTS **RESULTS BASED ON IN VIVO CLINICAL STUDY FOLLOWING REPEAT ORAL DOSING WITH 400 MG Q12H FOR 1 DAY, THEN 200 MG Q12H FOR AT LEAST 2 DAYS VORICONAZOLE TO HEALTHY SUBJECTS *** RESULTS BASED ON IN VIVO CLINICAL STUDY FOLLOWING REPEAT ORAL DOSING WITH 400 MG Q12H FOR 1 DAY, THEN 200 MG Q12H FOR 4 DAYS VORICONAZOLE TO SUBJECTS RECEIVING A METHADONE MAINTENANCE DOSE (30 TO 100 MG QD) **** NON-STEROIDAL ANTI-INFLAMMATORY DRUG ***** NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS', '1 NC DENOTES A MEAN CHANGE OF LESS THAN 10% 2 PEDIATRICS 3 MEAN INCREASE IN ADULTS AT HIGH OXCARBAZEPINE DOSES', 'CLINICAL\xc3\x82\xc2\xa0COMMENT', 'COMMENTS', 'PRESCRIBING\xc3\x82\xc2\xa0RECOMMENDATIONS', '* REFER TO PRECAUTIONS, DRUG INTERACTIONS FOR INFORMATION REGARDING TABLE.', 'RECOMMENDATIONS FOR VORICONAZOLE DOSAGE ADJUSTMENT/COMMENTS', '* CHANGE RELATIVE TO REFERENCE', "A) PREDICTIONS ARE BASED ON BANZEL CONCENTRATIONS AT THE MAXIMUM RECOMMENDED DOSE OF BANZEL. B) MAXIMUM CHANGES PREDICTED TO BE IN CHILDREN AND IN PATIENTS WHO ACHIEVE SIGNIFICANTLY HIGHER LEVELS OF BANZEL, AS THE EFFECT OF RUFINAMIDE ON THESE AEDS IS CONCENTRATION-DEPENDENT. C) LARGER EFFECTS IN CHILDREN AT HIGH DOSES/CONCENTRATIONS OF AEDS. D) PHENOBARBITAL, PRIMIDONE AND PHENYTOIN WERE TREATED AS A SINGLE COVARIATE (PHENOBARBITAL-TYPE INDUCERS) TO EXAMINE THE EFFECT OF THESE AGENTS ON BANZEL CLEARANCE. E) ALL COMPOUNDS OF THE BENZODIAZEPINE CLASS WERE POOLED TO EXAMINE FOR 'CLASS EFFECT' ON BANZEL CLEARANCE.", 'A\xc3\x82\xc2\xa0DECLINE\xc3\x82\xc2\xa0IN\xc3\x82\xc2\xa0GFR\xc3\x82\xc2\xa0OR\xc3\x82\xc2\xa0TUBULAR\xc3\x82\xc2\xa0SECRETION,\xc3\x82\xc2\xa0AS\xc3\x82\xc2\xa0FROM\xc3\x82\xc2\xa0ACE\xc3\x82\xc2\xa0INHIBITORS, ANGIOTENSIN RECEPTOR BLOCKERS, NONSTEROIDAL ANTI-INFLAMMATORY DRUGS [NSAIDS], COX-2 INHIBITORS MAY IMPAIR THE EXCRETION OF DIGOXIN.', 'SYSTEMIC EXPOSURE TO THESE DRUGS IS INCREASED SIGNIFICANTLY BY THE ADDITION OF KETOCONAZOLE: CONCOMITANT USE WITH KETOCONAZOLE IS CONTRAINDICATED.', '* THE INTERACTION BETWEEN IMMEDIATE-RELEASE VIRAMUNE AND THE DRUG WAS EVALUATED IN A CLINICAL STUDY. THE RESULTS OF DRUG INTERACTION STUDIES WITH IMMEDIATE-RELEASE VIRAMUNE ARE EXPECTED TO ALSO APPLY TO VIRAMUNE XR.', '\xc3\x82\xe2\x80\xa0\xe2\x80\x9c= DECREASED (INDUCES LAMOTRIGINE GLUCURONIDATION).', 'A = PLASMA CONCENTRATION INCREASED 25% IN SOME PATIENTS, GENERALLY THOSE ON A TWICE A DAY DOSING REGIMEN OF PHENYTOIN. B = IS NOT ADMINISTERED BUT IS AN ACTIVE METABOLITE OF CARBAMAZEPINE. NC = LESS THAN 10% CHANGE IN PLASMA CONCENTRATION. NE = NOT EVALUATED', '\xc3\x82\xe2\x80\xa0\xe2\x80\x98 INDICATES INCREASE.', '*CHANGE RELATIVE TO REFERENCE', 'FREQUENT MONITORING FOR ADVERSE EVENTS AND TOXICITY RELATED TO CALCIUM CHANNEL BLOCKERS. ADJUSTMENT OF CALCIUM CHANNEL BLOCKER DOSAGE MAY BE NEEDED.', '*REFER TO FOR INFORMATION REGARDING TABLE. PRECAUTIONS, DRUG INTERACTIONS', 'CLINICALCOMMENT', 'NO CLINICALLY SIGNIFICANT INTERACTION OBSERVED', 'RATIO (WITH/WITHOUT CRIXIVAN) OF COADMINISTERED DRUG PHARMACOKINETIC PARAMETERS (90% CI); NO EFFECT = 1.00', '*FIRST-DOSE VALUES; ALL OTHER PARAMETERS ARE LAST-DOSE VALUES', 'INCREASED RISK OF MYOPATHY/RHABDOMYOLYSIS ( 2 , 5.1 , 7 , 12.3 )', 'BLOOD DYSCRASIAS - SEE CANCER COLLAGEN VASCULAR DISEASE CONGESTIVE HEART FAILURE CONTRAINDICATIONS', 'CLINICAL COMMENTS', '*REFER TO PRECAUTIONS, DRUG INTERACTIONS FOR INFORMATION REGARDING TABLE.', 'A) THIS TABLE IS NOT ALL INCLUSIVE.', '*NOT ADMINISTERED BUT AN ACTIVE METABOLITE OF CARBAMAZEPINE.', '1 NC DENOTES A MEAN CHANGE OF LESS THAN 10%', 'NA \xc3\x82\xe2\x82\xac\xe2\x80\x9c NOT AVAILABLE * - 90% CONFIDENCE INTERVAL NOT REPORTED MEAN AZITHROMYCIN CONCENTRATIONS ONE DAY AFTER THE LAST DOSE WERE 53 NG/ML WHEN COADMINISTERED WITH 300 MG DAILY RIFABUTIN AND 49 NG/ML WHEN COADMINISTERED WITH PLACEBO.', 'DESCRIPTION', 'RISPERIDONE DOSE RECOMMENDATION', 'RISPERIDONE\xc3\x82\xc2\xa0DOSE RECOMMENDATION', 'NA - NOT AVAILABLE * - 90% CONFIDENCE INTERVAL NOT REPORTED MEAN RIFABUTIN CONCENTRATIONS ONE-HALF DAY AFTER THE LAST DOSE OF RIFABUTIN WERE 60 NG/ML WHEN COADMINISTERED WITH AZITHROMYCIN AND 71 NG/ML WHEN COADMINISTERED WITH PLACEBO.', 'CLINICAL COMMENT', 'CLINICAL RECOMMENDATIONS'], 'Interacting Substance': ['INTERACTING\xc3\x82\xc2\xa0DRUG', 'INTERACTING\xc3\x82\xc2\xa0AGENTS', 'INTERACTING AGENTS'], 'Interaction Properties': ['INTERACTIONINTERACTION', 'C MAX OF STAVUDINE (95% CI)', 'AUC SS(0-12H) (EXTENT OF SYSTEMIC EXPOSURE)', 'EFFECT ON ACTIVE MOIETY (RISPERIDONE + 9-HYDROXY-RISPERIDONE (RATIO*)', 'PLACEBO-SUBTRACTED MEAN MAXIMUM DECREASE IN SYSTOLIC BLOOD PRESSURE (MM HG)', 'AUC 0-\xc3\x82\xcb\x86\xc5\xbd', 'DISCRIPTION OF INTERACTION', 'AUC SS (0\xc3\x82\xe2\x82\xac\xe2\x80\x9c12H) (EXTENT OF SYSTEMIC EXPOSURE)', 'AUC', 'INTERACTION', 'C MAXSS (PEAK PLASMA CONCENTRATION)', 'C MAXSS (PEAKPLASMA CONCENTRATION)', 'C MAX (NG/ML)', '1 MEAN \xc3\x82\xc2\xb1 (\xc3\x8e\xc2\xbcG/G)', 'DRUG INTERACTIONS ASSOCIATED WITH INCREASED RISK OF MYOPATHY/RHABDOMYOLYSIS ( 2.6 , 5.1 , 7 , 12.3 )', 'DRUG PLASMA CONCENTRATION INCREASED BY ITRACONAZOLE', 'DESCRIPTION OF INTERACTION', 'DRUG INTERACTIONS ASSOCIATED WITH INCREASED RISK OF MYOPATHY/RHABDOMYOLYSIS ( 2.3 5.1, 7 , 12.3 )', 'MEAN (\xc3\x82\xc2\xb1SD)', 'TABLE 7: SUMMARY OF AED INTERACTIONS WITH OXCARBAZEPINE', 'TABLE III. DRUGS THAT HAVE BEEN DOCUMENTED NOT TO INTERACT WITH THEOPHYLLINE OR DRUGS THAT PRODUCE NO CLINICALLY SIGNIFICANT INTERACTION WITH THEOPHYLLINE*', 'DRUG INTERACTIONS ASSOCIATED WITH INCREASED RISK OF MYOPATHY/RHABDOMYOLYSIS ( 2.2 , 4 , 5.2 , 7.1 , 7.2 , 7.3 , 7.4 , 12.3 )', '\xc3\x82\xe2\x80\xa0\xe2\x80\x9c\xc3\x82\xc2\xa0= DECREASED (INDUCES LAMOTRIGINE GLURONIDATION). \xc3\x82\xe2\x80\xa0\xe2\x80\x98\xc3\x82\xc2\xa0= INCREASED (INHIBITS LAMOTRIGINE GLUCURONIDATION). ? = CONFLICTING DATA.', 'TABLE 2: DRUG-THYROIDAL AXIS INTERACTIONS', 'TYPE OF INTERACTION', 'SUPRANE (DESFLURANE, USP) MAC WITH FENTANYL OR MIDAZOLAM MEAN \xc3\x82\xc2\xb1 SD (PERCENT REDUCTION)', 'PLATELET INHIBITION INHIBITION OF PLATELET AGGREGATION WITH 5 MCM ADP (%)', 'AUCSS (0-12H) (EXTENT OF SYSTEMIC EXPOSURE)', 'C MAX', 'AUC SS(0\xc3\x82\xe2\x82\xac\xe2\x80\x9c12H) (EXTENT OF SYSTEMIC EXPOSURE)', 'CMAX', 'AUC SS(0-12H ) (EXTENT OF SYSTEMIC EXPOSURE)', 'TABLE 7 SUMMARY OF AED INTERACTIONS WITH OXCARBAZEPINE', 'OBSERVED DRUG INTERACTIONS', 'MEAN (\xc3\x82\xc2\xb1 SD)', 'C MAX SS (PEAK PLASMA CONCENTRATION)', 'DAY 5 AUC AT DAY 5 IS AUC 0\xc3\x82\xe2\x82\xac\xe2\x80\x9c24', '\xc3\x82\xe2\x80\xa0\xe2\x80\x9d INDICATES NO CHANGE, OR MEAN INCREASE OR DECREASE OF LESS THAN 10%.'], 'Interacting Substance Properties': ['TOPAMAX CONCENTRATION', 'DIGOXIN CONCENTRATIONS INCREASED > 50%', 'AUC OF DIDANOSINE (90% CI)', 'DOSE OF COADMINISTERED DRUG (MG)', 'AED CONCENTRATION', 'AUC OF STAVUDINE (95% CI)', 'TOPIRAMATE\xc3\x82\xc2\xa0CONCENTRATION', 'TOPIRAMATE CONCENTRATION', 'DOSE OF FOSAPREPITANT/ APREPITANT', 'DRUG PLASMA EXPOSURE (C MAX AND AUC \xc3\x8f\xe2\x80\x9e\xc3\x82\xc2\xa0)', '% CHANGE FROM PLAVIX (300 MG/75 MG) ALONE', 'DIDANOSINE DOSAGE', 'DIGOXIN CONCENTRATIONS INCREASED GREATER THAN 50%', 'DOSE SCHEDULES', 'AUC OF COADMINISTERED DRUG (95% CI)', 'DOSAGE ADJUSTMENT', 'C MAX OF COADMINISTERED DRUG (95% CI)', 'AUC 0\xc3\x82\xe2\x82\xac\xe2\x80\x9c\xc3\x82\xcb\x86\xc5\xbd', 'CMAX OF DIDANOSINE (90% CI)', 'TRILEPTAL DOSE (MG/DAY)', 'DRUG PLASMA EXPOSURE (C MAX AND AUC \xc3\x8f\xe2\x80\x9e )', 'DOSAGE OF MUSCLE RELAXANT CAUSING 95% DEPRESSION IN NEUROMUSCULAR BLOCKADE', 'VORICONAZOLE PLASMA EXPOSURE (C MAX AND AUC \xc3\x8f\xe2\x80\x9e AFTER 200 MG Q12H)', 'DOSING SCHEDULE', 'POSSIBLE MECHANISM'], 'Drug Name or Drug Class': ['DRUG CLASS', 'CLARITHROMYCIN', 'ALBUTEROL,', 'STAVUDINEDOSAGE', 'PIMOZIDE', 'NAME OF THE CONCOMITANT DRUG', 'DOSE OF AED (MG/DAY)', 'SPECIFIC DRUGS', 'DILTIAZEM', 'CLASSES\xc3\x82\xc2\xa0OF\xc3\x82\xc2\xa0DRUGS', 'ANTIBIOTICS NAFCILLIN RIFAMPIN', 'CO-ADMINISTERED DRUG', 'DRUGS', 'HIV ANTIVIRAL AGENTS: REVERSE TRANSCRIPTASE INHIBITORS', 'ASTEMIZOLE RIFABUTIN TACROLIMUS SHORT-ACTING BENZODIAZEPINES', 'ANTICONVULSANTS CARBAMAZEPINE OXCARBAZEPINE PHENOBARBITAL PHENYTOIN', 'ALBUTEROL, SYSTEMIC AND', 'GASTROINTESTINAL AGENTS', '1A2', '2C19', 'ANTIARRHYTHMICS', 'VARDENAFIL 10 MG PLACEBO-SUBTRACTED', 'ANTIPSYCHOTICS', 'ORAL HYPOGLYCEMICS COUMARIN-TYPE ANTICOAGULANTS PHENYTOIN CYCLOSPORINE', 'ANTI- INFLAMMATORY DRUGS', 'ANTINEOPLASTICS', 'CONCOMITANT DRUG NAME', 'GLUCOCORTICOIDS', 'VARDENAFIL 20 MG PLACEBO-SUBTRACTED', 'CONCOMITANT DRUG CLASS: DRUG\xc3\x82\xc2\xa0NAME', 'DRUG CLASS: DRUG NAME', 'DOSE OF POTIGA (MG/DAY)', 'GASTROINTESTINAL AGENTS CIMETIDINE RANITIDINE IMMUNOSUPPRESSIVES TACROLIMUS OTHER DRUGS FIBRIC ACID DERIVATIVES (E.G., BEZAFIBRATE, FENOFIBRATE)', 'PHENYTOIN', 'CONCOMITANT DRUG', 'OTHER DRUGS / DIETARY SUPPLEMENTS BOSENTAN OCTREOTIDE ORLISTAT ST. JOHN\xc3\x82\xe2\x82\xac\xe2\x84\xa2S WORT SULFINPYRAZONE TERBINAFINE TICLOPIDINE', 'AED CO-ADMINISTRATION', 'ANTIBIOTICS', 'SIMULTANEOUS DOSING OF VARDENAFIL 5 MG AND ALPHA-BLOCKER, PLACEBO-SUBTRACTED', 'IMMUNO-SUPPRESSIVES', 'AED\xc3\x82\xc2\xa0CO-ADMINISTERED', 'CLASSES OF DRUGS', 'NIZATIDINENORFLOXACIN', 'LOMEFLOXACIN', 'CONCOMITANT DRUG CLASS OR FOOD', 'MEBENDAZOLE', 'CIPROFLOXACIN, GENTAMICIN, TOBRAMYCIN, VANCOMYCIN, TRIMETHOPRIM WITH SULFAMETHOXAZOLE', 'PLAVIX PLUS', 'CYCLOSPORINE, HIV PROTEASE INHIBITORS (TIPRANAVIR PLUS RITONAVIR), HEPATITIS C PROTEASE INHIBITOR (TELAPREVIR)', 'CLASSES\xc3\x82\xc2\xa0OF\xc3\x82\xc2\xa0DRUG', 'DRUG', 'AZITHROMYCIN, CLARITHROMYCIN, ERYTHROMYCIN, QUINUPRISTIN/DALFOPRISTIN', 'OTHER DRUGS', 'NIZATIDINE', 'DRUG NAME', 'OTHER DRUGS/DIETARY SUPPLEMENTS', 'VIAGRA 100 MG', 'MEDROXYPROGESTERONE', 'EXAMPLES OF DRUGS', 'INTERACTING DRUG', 'ROXITHROMYCIN', 'ENZYME', 'COADMINISTERED DRUGS', 'AED', 'NSAIDS**** INCLUDING. IBUPROFEN AND DICLOFENAC (CYP2C9 INHIBITION)', 'DOFETILIDE', 'ALBUTEROL,\xc3\x82\xc2\xa0 SYSTEMIC AND INHALED', 'INHIBITORS', 'ANTINEOPLASTIC', 'IMMUNOSUPPRESSIVES', 'NAFCILLIN, RIFAMPIN', 'COADMINISTERED\xc3\x82\xc2\xa0DRUG', 'AED CO-ADMINISTERED', 'NORFLOXACIN', 'CONCOMITANT\xc3\x82\xc2\xa0DRUG', 'ANTINEOPLASTIC MELPHALAN ANTIFUNGALS AMPHOTERICIN B KETOCONAZOLE', 'OTHER DRUGS / DIETARY SUPPLEMENTS', 'EXAMPLES OF DRUGS WITHIN CLASS', 'DRUGS THAT MAY INCREASE SERUM THYROXINE-BINDING GLOBULIN (TBG) CONCENTRATION', 'DOSE OF CRIXIVAN (MG)', 'RIFAMPIN THEOPHYLLINE TERFENADINE CISAPRIDE', 'COADMINISTERED DRUG', 'CLARITHROMYCIN + OMEPRAZOLE', 'COUMARIN-TYPE ANTICOAGULANTS', 'DRUG/DRUG CLASS (MECHANISM OF INTERACTION BY VORICONAZOLE)', 'FINASTERIDE', 'ANTI-NEOPLASTICS', '2C9', 'ASENAPINE', 'INTERACTING DRUGINTERACTING DRUG', '3-HYDROXYDESLORATADINE', 'FAMOTIDINE', 'CONCOMITANTDRUG CLASS: DRUG NAME', 'DRUGS THAT MAY DECREASE SERUM TBG CONCENTRATION', 'OTHER DRUGS/DIETARYSUPPLEMENTS', 'DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS (CYP3A4 INHIBITION)', 'DRUGOR DRUG CLASS', 'ALPHA-BLOCKER', 'OXCARBAZEPINE DOSE (MG/DAY)', 'CONCOMITANT DRUG CLASS: SPECIFIC DRUGS', 'ANTI-INFLAMMATORY DRUGS', 'VIAGRA 25 MG', 'DRUG/DRUG CLASS (MECHANISM OF INTERACTION BY THE DRUG)', 'CALCIUM CHANNEL BLOCKERS', 'AED\xc3\x82\xc2\xa0COADMINISTERED', 'INDUCERS', 'RISPERIDONE', 'SUBSTANCE', 'ANTIFUNGALS', 'AED COADMINISTERED', 'ORAL HYPOGLYCEMICS', 'DRUG OR DRUG CLASS', 'DRUGS THAT AFFECT RENAL FUNCTION', 'ANTIBIOTICS CIPROFLOXACIN GENTAMICIN TOBRAMYCIN TRIMETHOPRIM WITH SULFAMETHOXAZOLE VANCOMYCIN', 'DRUGS\xc3\x82\xc2\xa0THAT\xc3\x82\xc2\xa0AFFECT\xc3\x82\xc2\xa0RENAL FUNCTION', 'DOSING OF VARDENAFIL 5 MG AND ALPHA-BLOCKER SEPARATED BY 6 HOURS, PLACEBO-SUBTRACTED', 'COADMINISTERED DRUG (POSTULATED EFFECT ON CYP450/UGT)', 'ALBUTEROL, SYSTEMIC AND INHALED', 'CONCOMITANT DRUG CLASS: DRUG NAME', 'ANTICONVULSANTS', 'INTERACTION DRUG', 'DOSE OF MIDAZOLAM', 'FELODIPINEFINASTERIDE', 'SPECIFIC DRUGS REPORTED', 'AED\xc3\x82\xc2\xa0CONCENTRATION', 'DILUENT', 'STAVUDINE DOSAGE', 'DRUGS THAT MAY REDUCE TSH SECRETION -THE REDUCTION IS NOT SUSTAINED; THEREFORE, HYPOTHYROIDISM DOES NOT OCCUR', 'DESLORATADINE', 'DRUGS WITH CLINICAL RECOMMENDATIONS REGARDING COADMINISTRATION (SEE PRECAUTIONS , DRUG INTERACTIONS )', 'ANTI-INFLAMMATORY DRUGS AZAPROPAZON COLCHICINE DICLOFENAC NAPROXEN SULINDAC', '3A4'], 'Effect on Drug': ['EFFECT ON CONCENTRATION OF AMPRENAVIR OR CONCOMITANT DRUG', 'EFFECT\xc3\x82\xc2\xa0ON\xc3\x82\xc2\xa0CONCENTRATION\xc3\x82\xc2\xa0OF\xc3\x82\xc2\xa0LAMOTRIGINE\xc3\x82\xc2\xa0OR\xc3\x82\xc2\xa0CONCOMITANT\xc3\x82\xc2\xa0DRUG', 'EFFECT ON CONCENTRATION OF LOPINAVIR OR CONCOMITANT DRUG', 'EFFECT ON ACTIVE MOIETY ( RISPERIDONE + 9-HYDROXY-RISPERIDONE (RATIO CHANGE RELATIVE TO REFERENCE )', 'EFFECT\xc3\x82\xe2\x82\xac', 'EFFECT ON ACTIVE MOIETY (RISPERIDONE + 9- HYDROXY-RISPERIDONE (RATIO CHANGE RELATIVE TO REFERENCE )', 'EFFECT ON CONCENTRATION OF RITONAVIR OR CONCOMITANT DRUG', 'EFFECT ON CONCENTRATION OF ATAZANAVIR OR CONCOMITANT DRUG', 'EFFECT ON LATUDA PHARMACOKINETICS', 'INFLUENCE OF AED ON MHD CONCENTRATION (MEAN CHANGE, 90% CONFIDENCE INTERVAL)', 'EFFECT ON ACTIVE MOIETY(RISPERIDONE + 9- HYDROXY- RISPERIDONE (RATIO*)', 'EFFECT ON CONCENTRATION INCREASE = \xc3\x82\xe2\x80\xa0\xe2\x80\x98; DECREASE = \xc3\x82\xe2\x80\xa0\xe2\x80\x9c; NO EFFECT = \xc3\x82\xe2\x80\xa0\xe2\x80\x9d', 'EFFECT ON CONCENTRATION', 'EFFECT ON ACTIVE MOIETY (RISPERIDONE + 9-HYDROXY- RISPERIDONE) (RATIO*)', 'EFFECT ON CONCENTRATION OF BOCEPREVIR OR CONCOMITANT DRUG', 'EFFECT ON CONCENTRATION OF SAQUINAVIR OR CONCOMITANT DRUG', 'RATIO (WITH/WITHOUT COADMINISTERED DRUG) OF INDINAVIR PHARMACOKINETIC PARAMETERS (90% CI); NO EFFECT = 1.00', 'INFLUENCE OF TRILEPTAL ON AED CONCENTRATION (MEAN CHANGE, 90% CONFIDENCE INTERVAL)', 'EFFECT ON ACTIVE MOIETY (RISPERIDONE + 9-HYDROXY-RISPERIDONE (RATIO CHANGE RELATIVE TO REFERENCE )', 'INFLUENCE OF AED ON POTIGA', 'EFFECT OF PAROXETINE ON OTHER DRUGS', 'INFLUENCE OF OXCARBAZEPINE ON CONCENTRATION (MEAN CHANGE, 90% CONFIDENCE INTERVAL)', 'EFFECT ON RIFABUTIN', 'EFFECT ON CONCENTRATION OF RALTEGRAVIR', 'EFFECT ON CONCENTRATION OF DARUNAVIR OR CONCOMITANT DRUG', 'EFFECT ON CONCENTRATION OF RILPIVIRINE OR CONCOMITANT DRUG', 'EFFECT\xc3\x82\xc2\xa0ON\xc3\x82\xc2\xa0ACTIVE MOIETY (RISPERIDONE\xc3\x82\xc2\xa0+\xc3\x82\xc2\xa09- HYDROXY- RISPERIDONE\xc3\x82\xc2\xa0(RATIO*)', 'INFLUENCE OF OXCARBAZEPINE ON AED CONCENTRATION (MEAN CHANGE, 90% CONFIDENCE INTERVAL)', 'EFFECT\xc3\x82\xc2\xa0ON\xc3\x82\xc2\xa0CONCENTRATION\xc3\x82\xc2\xa0OF LAMOTRIGINE\xc3\x82\xc2\xa0OR\xc3\x82\xc2\xa0CONCOMITANT\xc3\x82\xc2\xa0DRUG', 'EFFECT OF SALICYLATES', 'CLINICAL EFFECT(S)', 'EFFECT ON ACTIVE MOEITY (RISPERIDONE + 9-HYDROXY-RISPERIDONE) (RATIO CHANGE RELATIVE TO REFERENCE )', '* THE INTERACTION BETWEEN NEVIRAPINE AND THE DRUG WAS EVALUATED IN A CLINICAL STUDY. ALL OTHER DRUG INTERACTIONS SHOWN ARE PREDICTED.', 'EFFECT ON CONCENTRATION \xc3\x82\xe2\x80\xa0\xe2\x80\x98 = INCREASE, \xc3\x82\xe2\x80\xa0\xe2\x80\x9c = DECREASE, \xc3\x82\xe2\x80\xa1\xe2\x80\x9d = NO EFFECT', 'INFLUENCE OF POTIGA ON AED', 'EFFECTS OF SALICYLATES', 'EFFECT', 'EFFECT ON CONCENTRATION OF ETRAVIRINE OR CONCOMITANT DRUG', 'EFFECT AVERAGE EFFECT ON STEADY STATE THEOPHYLLINE CONCENTRATION OR OTHER CLINICAL EFFECT FOR PHARMACOLOGIC INTERACTIONS. INDIVIDUAL PATIENTS MAY EXPERIENCE LARGER CHANGES IN SERUM THEOPHYLLINE CONCENTRATION THAN THE VALUE LISTED.', 'EFFECT ON ACTIVEMOIETY (RISPERIDONE + 9- HYDROXY-RISPERIDONE(RATIO*)', 'EFFECTS ON STEADY-STATE FEXOFENADINE PHARMACOKINETICS AFTER 7 DAYS OF CO-ADMINISTRATION WITH FEXOFENADINE HYDROCHLORIDE 120 MG EVERY 12 HOURS (TWO TIMES THE RECOMMENDED TWICE DAILY DOSE) IN HEALTHY VOLUNTEERS (N=24)', 'EFFECT ON ACTIVE MOIETY(RISPERIDONE + 9- HYDROXY-RISPERIDONE (RATIO*)', 'DRUG INTERACTIONS', 'EFFECT\xc3\x82\xc2\xa0ON\xc3\x82\xc2\xa0ACTIVE MOIETY\xc3\x82\xc2\xa0(RISPERIDONE\xc3\x82\xc2\xa0+\xc3\x82\xc2\xa09- HYDROXY-\xc3\x82\xc2\xa0RISPERIDONE\xc3\x82\xc2\xa0(RATIO*)', 'EFFECT ON ACTIVE MOEITY (RISPERIDONE + 9-HYDROXY-RISPERIDONE (RATIO CHANGE RELATIVE TO REFERENCE )', 'EFFECT ON \xc3\x82\xc2\xa0CONCENTRATION OF LAMOTRIGINE OR CONCOMITANT DRUG', 'EFFECT ON CONCENTRATION OF LAMOTRIGINE OR CONCOMITANT DRUG', 'EFFECT ON CONCENTRATION OF INCIVEK OR CONCOMITANT DRUG', 'EFFECT ON CONCENTRATION OF TIPRANAVIR OR CONCOMITANT DRUG', 'EFFECT ON CONCENTRATION OF NEVIRAPINE OR CONCOMITANT DRUG', 'EFFECT ON ACTIVE MOIETY (RISPERIDONE + 9-HYDROXY-RISPERIDONE (RATIO * )', 'EFFECT ON ACTIVE MOIETY (RISPERIDONE + 9- HYDROXY-RISPERIDONE(RATIO*)', 'EFFECT ON ASENAPINE PHARMACOKINETICS', 'EFFECT ON COADMINISTERED DRUG', 'EFFECT OF CONCOMITANT DRUG ON PAROXETINE', 'CHANGE IN THE CONCENTRATION OF GANCICLOVIR OR CONCOMITANT DRUG', 'EFFECT ON CONCENTRATION OF DELAVIRDINE OR CONCOMITANT DRUG']}